Skip to content

US · NUVB · BIOTECHNOLOGY

Nuvation Bio Inc. (NUVB) intrinsic value and stock valuation

$3.80as of 2026-11-21 · Mkt cap 2.21B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nuvation Bio Inc. DCF and intrinsic value

InvestorsCraft values NUVB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NUVB’s statements →

Nuvation Bio Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10036 nuvationbio.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$62.9M
20182025
Net income
-$-204.63M
20182025
Free cash flow
-$-173.78M
20182025
Total equity
$305.7M+7.3% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$62.9M$7.87M$0.00$0.00$0.00
Operating income-$-213.06M-$-592.63M-$-99.82M-$-119.73M-$-93.32M
Net income-$-204.63M-$-567.94M-$-75.8M-$-104.2M-$-86.85M
EPSd-$-599.14K-$-2.11M-$-346.31K-$-480.8K-$-438.88K
Operating cash flow-$-173.43M-$-130.41M-$-68M-$-96.11M-$-68.19M
Capital expenditure-$-350K-$-160K-$-70K-$-370K-$-280K
Free cash flow-$-173.78M-$-130.57M-$-68.07M-$-96.48M-$-68.47M
Total assets$594.8M$540.6M$621.5M$672.1M$776.2M
Total debt$10.2M$8.91M$4.01M$4.26M$3.06M
Net debt-$-153.94M-$-26.81M-$-38.64M-$-96.84M-$-129.37M
Total equity$305.7M$463.8M$605.1M$655.1M$746M
Cash and short-term investments$529.2M$502.7M$611.2M$661M$765.4M
Income statement
20252024202320222021
Revenue$62.9M$7.87M$0.00$0.00$0.00
Cost of revenue$8.44M$7.08M$0.00$0.00$0.00
Gross profit$54.5M$800K$0.00$0.00$0.00
Research and development expenses$115.1M$524.2M$71.3M$87.8M$69M
Selling, general and administrative expenses$151.6M$69.2M$28.5M$31.9M$24.3M
Other expenses$860K$0.00$0.00$0.00$0.00
Operating expenses$267.5M$593.4M$99.8M$119.7M$93.3M
Cost and expenses$276M$600.5M$99.8M$119.7M$93.3M
Interest income$21.4M$27.1M$24.6M$7.45M$2.96M
Interest expense$13.7M$340K$0.00$0.00$0.00
Depreciation and amortization$1.74M$680K$220K$200K$180K
Ebitda-$-189.21M-$-566.91M-$-75.58M-$-104M-$-86.66M
Operating income-$-213.06M-$-592.63M-$-99.82M-$-119.73M-$-93.32M
Total other income/expenses, net$8.44M$24.7M$24M$15.5M$6.47M
Income before tax-$-204.63M-$-567.94M-$-75.8M-$-104.2M-$-86.85M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-204.63M-$-567.94M-$-75.8M-$-104.2M-$-86.85M
Weighted average shares outstanding$341.5M$268.8M$218.9M$216.7M$197.9M
Weighted average diluted shares outstanding$341.5M$268.8M$218.9M$216.7M$197.9M
Balance sheet
20252024202320222021
Cash and short-term investments$529.2M$502.7M$611.2M$661M$765.4M
Net receivables$19.4M$16.3M$3.7M$2.48M$3.04M
Inventory$11.4M$0.00$0.00$0.00$0.00
Total current assets$571.5M$526.3M$616.4M$667.3M$772.1M
Property, plant and equipment, net$4.48M$2.99M$4.32M$4.68M$3.66M
Goodwill and intangible assets$11.2M$4.62M$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$23.3M$14.4M$5.05M$4.82M$4.08M
Total assets$594.8M$540.6M$621.5M$672.1M$776.2M
Accounts payable$9.48M$6.35M$2.21M$2.14M$3.92M
Short-term debt$7.6M$7.95M$1.97M$1.21M$860K
Deferred revenue$0.00$11.1M$0.00$0.00$0.00
Total current liabilities$82.2M$58.2M$14M$13.2M$16.9M
Long-term debt$2.54M$970K$2.04M$3.05M$2.19M
Deferred revenue, non-current$145.8M$15.6M$0.00$0.00$0.00
Total non-current liabilities$206.9M$18.6M$2.39M$3.9M$13.2M
Capital lease obligations$0.00$2.63M$4.01M$4.26M$3.06M
Total liabilities$289.1M$76.8M$16.4M$17.1M$30.2M
Common stock$1.42B$1.37B$947.8M$927.6M$910M
Retained earnings-$-1.12B-$-910.74M-$-342.8M-$-267M-$-162.8M
Accumulated other comprehensive income (loss)-$-190K$570K$180K-$-5.53M-$-1.19M
Total equity$305.7M$463.8M$605.1M$655.1M$746M
Total investments$365.1M$467M$568.6M$559.9M$633M
Total debt$10.2M$8.91M$4.01M$4.26M$3.06M
Net debt-$-153.94M-$-26.81M-$-38.64M-$-96.84M-$-129.37M
Cash flow statement
20252024202320222021
Net income-$-204.63M-$-567.94M-$-75.8M-$-104.2M-$-86.85M
Depreciation and amortization$1.74M$680K$220K$200K$180K
Stock-based compensation$35.9M$32.3M$19.5M$16.3M$9.27M
Change in working capital-$-11.98M-$-12.51M$540K-$-3.45M$4.79M
Accounts receivable-$-3.07M-$-12.59M-$-1.22M$550K-$-1.95M
Inventory-$-11.41M$0.00$0.00$0.00$0.00
Accounts payable$3.13M-$-1.65M$70K-$-1.79M$1.86M
Net cash provided by operating activities-$-173.43M-$-130.41M-$-68M-$-96.11M-$-68.19M
Investments in property, plant and equipment-$-8.35M-$-160K-$-70K-$-370K-$-280K
Acquisitions, net$0.00$12.4M$0.00$0.00$0.00
Net cash used for investing activities$99.5M$122.7M$8.92M$63.5M-$-454.67M
Common stock issued$11.4M$4.88M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$202.5M$330K$630K$1.33M$625.5M
Net change in cash$128.4M-$-6.93M-$-58.45M-$-31.32M$102.7M
Cash at end of period$164.1M$35.7M$42.7M$101.1M$132.4M
Operating cash flow-$-173.43M-$-130.41M-$-68M-$-96.11M-$-68.19M
Capital expenditure-$-350K-$-160K-$-70K-$-370K-$-280K
Free cash flow-$-173.78M-$-130.57M-$-68.07M-$-96.48M-$-68.47M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nuvation Bio Inc.

        Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.

        CEO
        David T. Hung
        Employees
        298
        Beta
        1.53

        Explore

        Frequently asked questions

        What is the intrinsic value of Nuvation Bio Inc. (NUVB)?

        InvestorsCraft does not currently publish an intrinsic value for NUVB. How the IC value is calculated.

        Is NUVB undervalued?

        InvestorsCraft does not publish an undervaluation signal for NUVB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.